 |
6 Products |  |
6 Diseases | | 6 Products |
|
995 Trials |  |
3123 News |  |
| «12...3940414243444546474849...5253» |
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: CAP-ACE: TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma (clinicaltrials.gov) - Sep 22, 2020
P2, N=188, Recruiting, Sponsor: Zhongda Hospital
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer (clinicaltrials.gov) - Sep 22, 2020
P2, N=10, Recruiting, Sponsor: Peking Union Medical College Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P1/2 trial: Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer (clinicaltrials.gov) - Sep 21, 2020
P1/2, N=30, Not yet recruiting, Sponsor: Wuhan Union Hospital, China
- ||| AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer (clinicaltrials.gov) - Sep 19, 2020
P=N/A, N=40, Recruiting, Sponsor: Qianfoshan Hospital
Not yet recruiting --> Recruiting
- || AiRuiKa (camrelizumab) / Incyte
Clinical, Journal, Mismatch Repair, Microsatellite Instability: Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high: an open-label prospective pivotal trial. (Pubmed Central) - Sep 18, 2020
Not yet recruiting --> Recruiting Camrelizumab provided durable objective response and disease control in pre-treated patients with dMMR/MSI-H advanced or metastatic solid tumour, being a promising treatment option for these patients.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, PD(L)-1 Biomarker, IO biomarker: Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) - Sep 13, 2020
P2, N=27, Not yet recruiting, Sponsor: Sun Yat-sen University
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, PD(L)-1 Biomarker, IO biomarker: Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) - Sep 13, 2020
P2, N=25, Not yet recruiting, Sponsor: Sun Yat-sen University
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Safety and Efficacy of PD-1 Antibody SHR-1210 Combined with Concurrent Chemoradiotherapy to Treat Locally Advanced Esophageal Squamous Cell Carcinoma: a Phase Ib Clinical Trial (Science Center, Oral Scientific Sessions) - Sep 13, 2020 - Abstract #ASTRO2020ASTRO_1389;
P=N/A
The results from our original phase Ib clinical trial revealed that dCCRT combined with SHR-1210 exhibited a remarkable therapeutic effect with tolerable toxicity, which would provide a new strategy for LAESCC. Phase III clinical trial is ongoing to confirmed the present results.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion date, Trial initiation date, Trial primary completion date: Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Sep 8, 2020
P=N/A, N=150, Not yet recruiting, Sponsor: Sun Yat-sen University
Phase III clinical trial is ongoing to confirmed the present results. Trial completion date: Jul 2025 --> Oct 2025 | Initiation date: Jul 2020 --> Oct 2020 | Trial primary completion date: Jul 2023 --> Oct 2023
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment change: Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer (clinicaltrials.gov) - Sep 8, 2020
P1/2, N=30, Recruiting, Sponsor: Wuhan Union Hospital, China
Trial completion date: Jul 2025 --> Oct 2025 | Initiation date: Jul 2020 --> Oct 2020 | Trial primary completion date: Jul 2023 --> Oct 2023 N=50 --> 30
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer (clinicaltrials.gov) - Sep 7, 2020
P2, N=23, Not yet recruiting, Sponsor: Sun Yat-sen University
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab combined with apatinib for refractory gestational trophoblastic neoplasia: A phase 2, single-arm, prospective Study () - Sep 3, 2020 - Abstract #IGCS2020IGCS_453;
The combination of camrelizumab and apatinib demonstrated tolerable toxicity and showed encouraging activity in patients with refractory GTN. Larger clinical trials of predictive biomarkers of response are needed.
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: YOUNGBC-11: First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients (clinicaltrials.gov) - Sep 2, 2020
P2, N=90, Recruiting, Sponsor: Fudan University
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: A Phase ? Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Aug 30, 2020
P2, N=42, Not yet recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC (clinicaltrials.gov) - Aug 27, 2020
P2, N=30, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- || AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open, Trial primary completion date: Neo-PLANET: Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach Adenocarcinoma (clinicaltrials.gov) - Aug 25, 2020
P2, N=36, Recruiting, Sponsor: Shanghai Zhongshan Hospital
Larger clinical trials of predictive biomarkers of response are needed. Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2019 --> Dec 2020
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer (clinicaltrials.gov) - Aug 20, 2020
P2, N=27, Not yet recruiting, Sponsor: Beijing Tsinghua Chang Gung Hospital
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 20, 2020
P=N/A, N=514, Not yet recruiting, Sponsor: Shanghai Zhongshan Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell (clinicaltrials.gov) - Aug 20, 2020
P2, N=60, Recruiting, Sponsor: Fudan University
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: NACI: Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer (clinicaltrials.gov) - Aug 17, 2020
P2, N=84, Not yet recruiting, Sponsor: Huazhong University of Science and Technology
- || AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion: Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer (clinicaltrials.gov) - Aug 17, 2020
P2, N=25, Completed, Sponsor: Hangzhou Cancer Hospital
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2019 --> Dec 2020 Recruiting --> Completed
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02) (clinicaltrials.gov) - Aug 16, 2020
P2, N=52, Recruiting, Sponsor: Yu jiren
- | Epidaza (chidamide) / Chipscreen, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment change: CHN-PLAGH-BT-045: Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma (clinicaltrials.gov) - Aug 13, 2020
P2, N=100, Recruiting, Sponsor: Chinese PLA General Hospital
Recruiting --> Completed N=280 --> 100
- | Epidaza (chidamide) / Chipscreen, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma. (clinicaltrials.gov) - Aug 13, 2020
P2, N=200, Recruiting, Sponsor: Chinese PLA General Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer (clinicaltrials.gov) - Aug 12, 2020
P2, N=63, Recruiting, Sponsor: Zhejiang Cancer Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2/3 trial: Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov) - Aug 11, 2020
P2/3, N=100, Recruiting, Sponsor: Chinese PLA General Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: FDZL-PFG: Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma?FDZL-GC001 Trial (clinicaltrials.gov) - Aug 11, 2020
P2, N=40, Recruiting, Sponsor: Fudan University
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P1 trial: McCrest-2: Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2) (clinicaltrials.gov) - Aug 11, 2020
P1, N=20, Recruiting, Sponsor: Ruijin Hospital
- ||| AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer (clinicaltrials.gov) - Aug 10, 2020
P=N/A, N=40, Not yet recruiting, Sponsor: Qianfoshan Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P1 trial: Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1) (clinicaltrials.gov) - Aug 10, 2020
P1, N=20, Recruiting, Sponsor: Ruijin Hospital
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 9, 2020
P2, N=74, Not yet recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P1/2 trial: Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Aug 9, 2020
P1/2, N=26, Recruiting, Sponsor: Zhejiang Cancer Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC (clinicaltrials.gov) - Aug 7, 2020
P2, N=40, Recruiting, Sponsor: Hebei Medical University Fourth Hospital
N=280 --> 100 Not yet recruiting --> Recruiting
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open, Trial initiation date: Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor (clinicaltrials.gov) - Aug 7, 2020
P2, N=180, Recruiting, Sponsor: Hebei Medical University Fourth Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Apr 2020 --> Jul 2020
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: LungMate-003: Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov) - Aug 7, 2020
P2, N=99, Recruiting, Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Not yet recruiting --> Recruiting | Initiation date: Apr 2020 --> Jul 2020 Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial: Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer. (clinicaltrials.gov) - Aug 6, 2020
P3, N=45, Not yet recruiting, Sponsor: Fuzhou General Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer (clinicaltrials.gov) - Aug 6, 2020
P2, N=117, Recruiting, Sponsor: Fudan University
- | AiRuiKa (camrelizumab) / HLB Bio Group
New trial, Real-world evidence: Camrelizumab Utilization on Patients With Advanced Liver Cancer (clinicaltrials.gov) - Jul 26, 2020
P=N/A, N=1000, Not yet recruiting, Sponsor: First Affiliated Hospital Xi'an Jiaotong University
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: CARD: Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL (clinicaltrials.gov) - Jul 26, 2020
P1/2, N=33, Recruiting, Sponsor: Huiqiang Huang
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Application of anti-PD1 drugs before or during thoracic radiotherapy increases the incidence of radiation pneumonia compared to the application after radiotherapy (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2643;
Legal entity responsible for the study: Xiangzhi Zhu. Funding: Has not received any funding.
- paclitaxel / Generic mfg.
[VIRTUAL] Changes in the tumour immune microenvironment in oesophageal squamous cell carcinoma patients receiving different neoadjuvant therapies (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2277;
Carboplatin combined with paclitaxel is administered as chemotherapy for three weeks per cycle (Q3W), 2 cycles...Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Efficacy of camrelizumab (SHR-1210) plus apatinib as second-line treatment for advanced squamous NSCLC (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2047;
P2
Funding: Jiangsu Hengrui Medicine Co., Ltd. Clinical trial identification: NCT03083041.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab in the treatment of patients with local advanced/metastatic esophageal squamous cell carcinoma (ESCC): A multi-center, prospective, cohort study (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1833;
Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- Opdivo (nivolumab) / Ono Pharma, BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] PD1midKLRG1+Tbethigh effector memory T in the peripheral blood correlates with tumor response to combined therapy with lenvatinib and anti-PD-1 antibodies in unresectable hepatocellular carcinoma (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1808;
Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] A phase II study of camrelizumab for advanced hepatocellular carcinoma: Two-year outcomes and continued treatment beyond RECIST-defined progression (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1792;
P2
Ltd, China. Clinical trial identification: CTR20160871, Nov 14, 2016; NCT02989922, Dec 12, 2016.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (RESCUE): An open-label, multi-center, phase II trial (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1790;
P2
Funding: Jiangsu Hengrui Medicine Co., Ltd. Clinical trial identification: NCT03463876.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] A single-arm, open-label, multicenter phase II study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥2 lines of chemotherapy: CAPTAIN study (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1426;
P2
Funding: Jiangsu Hengrui Medicine Co., Ltd. Clinical trial identification: NCT03558191; CTR20180865.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] An open-label, single-center, phase II, single-arm trial of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1423;
P2
Funding: Jiangsu Hengrui Medicine Co., Ltd. Clinical trial identification: NCT03701022.
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: MA-HCC-?-003: Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients (clinicaltrials.gov) - Jul 22, 2020
P2, N=60, Enrolling by invitation, Sponsor: Shanghai Zhongshan Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P1/2 trial: A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast (clinicaltrials.gov) - Jul 21, 2020
P1/2, N=20, Recruiting, Sponsor: Jiangxi Provincial Cancer Hospital